NIH Clinical Trial Of Investigational Vaccine For COVID-19 Begins Covid-19 Vaccine Update

News Release

Monday, March 16, 2020

Study enrolling Seattle-based healthy adult volunteers.

3D print on a spike protein on SARS-CoV-2—also known when 2019-nCoV, the virus that causes COVID-19—in front on a 3D print on a SARS-CoV-2 virus particle. The spike protein (foreground) enables the virus to enter including infect human cells. On the virus model, the virus surface (blue) is covered with spike proteins (red) that enable the virus to enter including infect human cells. For more information, call on NIH

A Phase 1 unemotional case evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) inside Seattle. The . The open-label case determination enroll 45 healthy adult volunteers ages 18 to 55 years over about 6 weeks. The first participant received the investigational vaccine today.

The study is evaluating different doses on the experimental vaccine for safety including its ability to produce an immune answer inside participants. This is the first on multiple steps inside the unemotional case means for evaluating the potential benefit on the vaccine.

The vaccine is called mRNA-1273 including was developed by NIAID scientists including their collaborators at the biotechnology company Moderna, Inc., based inside Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing on the vaccine candidate for the Phase 1 unemotional trial.

“Finding a safe including effective vaccine to prevent condition with SARS-CoV-2 is an urgent public condition priority,” said NIAID Director Anthony S. Fauci, M.D. “This Phase 1 study, launched inside record speed, is an important first step toward achieving that goal.”

Infection with SARS-CoV-2, the virus that causes COVID-19, can cause a mild to severe respiratory illness including include symptoms on fever, cough including shortness on breath. COVID-19 cases were first identified inside December 2019 inside Wuhan, Hubei Province, China. As on March 15, 2020, the .

Currently, no approved vaccines exist to prevent condition with SARS-CoV-2.

The investigational vaccine was developed using a genetic platform called mRNA (messenger RNA). The investigational vaccine directs the body’s cells to state a virus protein that it is hoped determination elicit a robust immune response. The mRNA-1273 vaccine has shown pledge inside creature models, including this is the first case to examine it inside humans.

Scientists at NIAID’s Vaccine Research Center (VRC) including Moderna were experienced to quickly advance mRNA-1273 as on prior studies on related coronaviruses that cause severe acute respiratory syndrome (SARS) including Middle East respiratory syndrome (MERS). Coronaviruses are spherical including have spikes protruding from their surface, giving the particles a crown-like appearance. The spike binds to human cells, allowing the virus to acquire entry. VRC including Moderna scientists already were working supported by an investigational MERS vaccine targeting the spike, which provided a head start for developing a vaccine candidate to protect against COVID-19. Once the genetic information on SARS-CoV-2 became available, the scientists quickly selected a succession to state the stabilized spike protein on the virus inside the existing mRNA platform.

The Phase 1 case is led by Lisa A. Jackson, M.D., senior investigator at KPWHRI. Study participants determination accept two doses on the vaccine via intramuscular vaccination inside the upper arm about 28 days apart. Each participant determination be assigned to accept a 25 microgram (mcg), 100 mcg or 250 mcg dose at both vaccinations, with 15 people inside every dose cohort. The first four participants determination accept single vaccination with the low dose, including the next four participants determination accept the 100 mcg dose. Investigators determination review safety data before vaccinating the remaining participants inside the 25 including 100 mcg dose groups including before participants accept their second vaccinations. Another safety review determination be done before participants are enrolled inside the 250 mcg cohort.

Participants determination be asked to go back to the clinic for follow-up visits between vaccinations including for additional visits across the span on a year after the second shot. Clinicians determination monitor participants for common vaccination symptoms, such when soreness at the vaccination site or fever when well when any other medical issues. A manners team determination meet regularly to review safety data, including a safety monitoring committee determination also periodically review case data including advise NIAID. Participants also determination be asked to provide blood samples at specified time points, which investigators determination test inside the laboratory to detect including measure the immune answer to the experimental vaccine.

“This work is critical to national efforts to respond to the threat on this emerging virus,” Dr. Jackson said. “We are prepared to conduct this important case as on our experience when an NIH unemotional trials center since 2007.”

Adults inside the Seattle area who are interested inside joining this study should call on .

NIAID conducts including supports research — at NIH, throughout the United States, including worldwide — to study the causes on spreading including immune-mediated diseases, including to advance better means on preventing, diagnosing including treating these illnesses. News releases, fact sheets including other NIAID-related materials are available supported by the .

About the National Institutes on Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes including Centers including is a component on the U.S. Department on Health including Human Services. NIH is the primary federal agency conducting including supporting basic, clinical, including translational medical research, including is investigating the causes, treatments, including cures for both common including rare diseases. For more information on NIH including its programs, call on .

NIH…Turning Discovery Into Health^®

Note

Adults inside the Seattle area who are interested inside joining this study should call on . People who live outside on this region determination not be eligible to participate inside this trial.

###

 

Share this post